Gabapentinoid

Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

Wednesday, September 15, 2021 - 4:15pm

QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.

Key Points: 
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.
  • Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.
  • Neuros Medical, a neuromodulation company, has developed the Altius system for the treatment of chronic post-amputation pain (phantom limb pain and residual limb pain).
  • Post-amputation pain includes both phantom limb and residual limb (or "stump") pain, and impacts nearly one million Americans.

Neuros Medical Receives FDA Breakthrough Device Designation for its Novel AltiusĀ® High Frequency Nerve Block System

Tuesday, June 29, 2021 - 1:06pm

Chronic post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.

Key Points: 
  • Chronic post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.
  • Neuros anticipates completion of enrollment in its pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study by the Fall of 2021.
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable chronic post-amputation pain.
  • Neuros Medical, a neuromodulation company, has developed the Altius system for the treatment of chronic post-amputation pain (Phantom Limb Pain and Residual Limb Pain).